钠-葡萄糖共转运蛋白2抑制剂与2型糖尿病患者泌尿生殖系统感染风险的Meta分析  

Meta-analysis of sodium-glucose cotransporter 2 inhibitors and risk of urinary tract infection and genital infection in patients with type 2 diabetes mellitus

作　　者：谷优优[1] 张丽[1] 索艳[1] 王维清[1] 姜云生[1] 王肃[1] 刘晓智[2,3] CU You-you;HANG Li;SUO Yan;WANG Wei-qing;JIANG Yun-sheng;WANG Su;LIU Xiao-zi(Department of Endocrinology,the Fifth Central Hospital of Tianjin,TIANJIN 300450,China;Hospital Central Laboratory,the Fifth Central Hospital of Tianjin,TIANJIN 300450,China;Tianjin Key Laboratory of Organ Development Epigenetics of Premature Infants,TIANJIN 300450,China)

机构地区：[1]天津市第五中心医院内分泌科,天津300450 [2]天津市第五中心医院医院中心实验室,天津300450 [3]天津市早产儿器官发育表观遗传重点实验室,天津300450

出　　处：《中国新药与临床杂志》2024年第2期148-154,共7页Chinese Journal of New Drugs and Clinical Remedies

基　　金：国家自然科学基金(81471175);天津市自然科学基金(19JCQNJC11900)。

摘　　要：目的评价钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂与2型糖尿病(T2DM)患者泌尿生殖系统感染风险的关系。方法计算机检索中国生物医学文献、万方、中国知网、Cochrane Library、PubMed数据库,检索时限为建库至2020年12月31日,收集关于SGLT-2抑制剂与T2DM患者泌尿生殖系统感染风险关系的随机对照研究,采用RevMan 5.4软件进行Meta分析。结果最终纳入27项研究,共22572例患者。Meta分析结果显示,SGLT-2抑制剂不增加T2DM患者泌尿系统感染的风险(OR=1.07,95%CI:0.94~1.21,P=0.29)。亚组分析显示,在不同SGLT-2抑制剂、干预周期、性别分层下,SGLT-2抑制剂均不增加T2DM患者泌尿系统感染风险(P>0.05)。与对照组相比,SGLT-2抑制剂显著增加了T2DM患者生殖系统感染的风险(OR=4.14,95%CI:3.45~4.97,P<0.05)。亚组分析显示,在不同类型SGLT-2抑制剂、干预周期、性别分层下,均发现SGLT-2抑制剂显著增加T2DM患者生殖系统感染风险(P<0.01)。结论SGLT-2抑制剂可增加T2DM患者生殖系统感染的风险,并未增加T2DM患者泌尿系统感染的风险。AIM To evaluate the association between the sodium-glucose cotransporter 2(SGLT-2)inhibitors and urinary tract infection and genital infection in patients with type 2 diabetes mellitus(T2DM).METHODS The Chinese Biomedical Literature,Wanfang,CNKI,Cochrane Library and PubMed were searched to collected randomized controlled trial studies about the relationship between SGLT-2 inhibitors and the risk of urinary tract infection and genital infection in patients with T2DM,and the search deadline was December 31,2020.Meta-analysis was conducted by RevMan version 5.4software.RESULTS Twenty-seven studies enrolling 22572 participants were selected.The results of meta-analysis showed that SGLT-2 inhibitors did not increase the risk of urinary tract infection in patients with T2DM(OR=1.07,95%CI:0.94 to 1.21,P=0.29).In subgroup analysis of different SGLT-2 inhibitor,intervention cycle,and gender,SGLT-2 inhibitors did not increase the risk of urinary tract infection in patients with T2DM(P>0.05).SGLT-2 inhibitors significantly increased the risk of genital infection in patients with T2DM(OR=4.14,95%CI:3.45 to 4.97,P<0.01)compared to the control group.Subgroup analysis showed that SGLT-2 inhibitors were found to significantly increase the risk of genital infection in patients with T2DM for different SGLT-2 inhibitor,intervention cycle,and gender(P<0.01).CONCLUSION SGLT-2 inhibitors can increase the risk of genital infection in patients with T2DM,but don't increase the risk of urinary tract infection in T2DM patients.

关 键 词：钠-葡萄糖共转运蛋白2抑制剂 糖尿病 2型 泌尿生殖系统 感染 META分析 

分 类 号：R977.1[医药卫生—药品]